机构地区:[1]天津市天津医院,天津300211 [2]天津医科大学药理学教研室,天津300070 [3]天津市第三中心医院人工细胞重点实验室,天津300170 [4]天津市第三中心医院检验科,天津300170
出 处:《中国医院药学杂志》2012年第24期1947-1951,共5页Chinese Journal of Hospital Pharmacy
基 金:天津市应用基础研究计划重点项目(编号:06YFJZJC 02900)
摘 要:目的:探讨秋水仙碱在体外抗乙型肝炎病毒(HBV)的作用。方法:以秋水仙碱作用于HBV全基因组转染的人肝癌细胞株(Hep G22.2.15),用罗氏电化学发光免疫分析仪检测HBsAg和HBeAg,用ABI7000荧光定量PCR扩增仪检测细胞内、外HBV-DNA、HBV-共价闭环DNA(HBV-cccDNA)(copies/cell)。数据表示为l g(x珚±s)。结果:(1)秋水仙碱6.25×10-6~1×10-4 mol·L-1能显著抑制Hep G22.2.15产生/分泌HBsAg(P<0.05,P<0.01),IC50=1.473×10-7 mol·L-1,其3.125×10-6和2.5×10-5~1×10-4 mol·L-1能显著抑制Hep G22.2.15产生/分泌HBeAg(P<0.05,P<0.01),IC50=2.387×10-7 mol·L-1,拉米夫定(lamivudine)IC50分别为3.52×10-4 mol·L-1和3.184×10-3 mol·L-1。(2)秋水仙碱和拉米夫定有类似的降低Hep G22.2.15细胞内HBV-DNA的作用(P<0.05),IC50分别为9.747×10-9 mol·L-1和2.649×10-6 mol·L-1。(3)秋水仙碱3.125×10-6和6.25×10-6 mol·L-1能明显减少Hep G22.2.15细胞内和上清液中HBV-cccDNA(P<0.05)。(4)秋水仙碱1.6×10-6~1×10-3 mol·L-1和拉米夫定2×10-4,1×10-3 mol·L-1皆能显著抑制Hep G22.2.15细胞增殖(P<0.05,P<0.01),IC50分别为7.933×10-6 mol·L-1和2.60×10-4 mol·L-1。结论:秋水仙碱在体外具有抗HBV的作用,包括降低HBsAg和HBeAg的产生/分泌,减低Hep G22.2.15细胞内、外HBV-cccDNA水平,减少细胞内HBV-DNA,且主要是由于直接抑制HBV-DNA和HBV-cccDNA的产生。OBJECtiVE To explore the inhibitory effect of colchicine on hepatitis B virus(HBV) in vitro.METHODS Hep (32 2. 2. ] 5 eell strain was stimulated by colchicine. HBsAg and HBeAg were measured with Roche diagnostics gleesys im- munoassay system, and the intraeellular and extracellular HBV-DNA and HBV-covalently elosed eircular DNA(HBV-cccDNA) (copies/ceil) were quantitated by ABI7000 I.ightCyeler PCR. All values were denoted as 1 g(x±s). RESULTS First, 6. 25 ×10^-6mol·L^-1 - 1×10^-4mol·L^-1 colchicine significantly inhibited Hep (32 2. 2. 15 cell strain from producing/secreting HBsAg (P〈0. 05, P〈0.01), IC50 was 1. 473 ×10^-7mol·L^-1. Besides, 3. 125 ×10^-6mol·L^-1 and 2. 5 ×10^-5mol·L^-1-1 ×10^-4mol·L^-1 colchicine markedly inhibited Hep (32 2. 2. 15 cell strain from producing/secreting HBeAg (P〈0. 05, P〈0. 01), IC50 was 2. 387×10^-7mol·L^-1. For lamivudine, ICs0 was 3.52×10^-4mol·L^-1and 3. 184×10^-3mol·L^-1 respectively. Second, both colchicine and lamivudine could reduce the HBV-DNA in Hep (32 2. 2. 15 cell strain significantly (P〈0. (55), and the ICs0 of eolehieine and lamivudine were 9. 747×10^-9mol·L^-1 and 2. 649 ×10^-6mol·L^-1 respectively. Third, 3. 125 ×10^-6mol·L^-1 and 6. 25 ×10^-6mol·L^-1 colehicine significantly reduced the HBV cccDNA in Hep G2 2. 2. 15 cell strain and in supernate (P〈0.05). Fourth, colchicine of 1.6 ×10^-6mol·L^-1- 1 ×10^-3mol·L^-1 and lamivudine of 2 ×10^-4mol·L^-1 and 1 ×10^-3mol·L^-1 significantly inhibited Hep (32 2. 2. 15 cell proliferation (P〈0. 1)5, P〈0. 01), Ies0 was 7. 933 ×10^-6mol·L^-1 and 2. 615 ×10^-4mol·L^-1 respectively. CONCLUSION The results suggest that eolchicine has inhibitory effects on hepatitis B virus in vitro by reducing the production/secretion of HBsAg and HBeAg, decreasing intracellular and extraeellular HBV-cccDNA and intracel- lular HBV-DNA. The effects are primarily due to directly inhibiting the production of HBV DNA and HBV cccDNA.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...